Dong-A ST
Headquarters
Sites
Regulatory compliance
Company description
Dong-A has held the position of the largest pharmaceutical company in Korea since 1967. Our predominant market presence is attributed to internally developed products such as Suganon tab, Evogliptin, which is a DPP-4 inhibitor for type 2 diabetes mellitus, Zydena tab, which is Udenafil, the fourth PDE5 inhibitor globally for erectile dysfunction, Stillen tab, a herbal treatment for gastritis with Eupatilin, and Motilitone tab, which contains Corydaline for functional dyspepsia. Additionally, we provide branded generic drugs (anti-cancer, anti-TB, etc.), bio-pharmaceutical, IMD, APIs, and OTC products.